Mar 16,2021

Israel's DreaMed, Yale team up on AI diabetes monitoring

Israeli medical software company DreaMed Diabetes said on Monday it was partnering with Yale New Haven Health System to use artificial intelligence (AI) in monitoring insulin and glucose levels in children with Type 1 diabetes. DreaMed’s dose-optimisation software will be tested on 100 diabetic children at Yale New Haven Children’s Hospital, said Jennifer Sherr, a pediatric endocrinologist there. The subjects will use the system at least every three weeks, “and then we’ll see them in clinical follow-up at three months, and again at six months” to assess whether their overall control had improved, she said, noting the follow-ups could be virtual. The software uses patient data to create recommendations for insulin dose changes, if required.

COLLABORATION PARTNERSHIP

#r&d

#rpm

View Analyst & Ambassador Comments
Go to original news
Mar 18,2021

Initiating our First Clinical Study of our Continuous Glucose Monitoring Sensor

GROUND-BREAKING SUBCUTANEOUS SENSOR AIMS TO CONTINUOUSLY MONITOR MULTIPLE METABOLITES INCLUDING KETONES IN PEOPLE LIVING WITH DIABETES

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Mar 20,2021

Insulet’s Omnipod® 5 Automated Insulin Delivery System Improves Clinical Outcomes in Type 1 Diabetes

Omnipod 5, the world’s first tubeless, wearable system that continuously adapts insulin delivery based on glucose levels and trends, significantly improved time in range and reduced HbA1c in children, adolescents, and adults, aged 6-70 years, with type 1 diabetes.

CLINICAL STUDY

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Mar 21,2021

Actiste® Mini receives market approval in the United Arab Emirates

Brighter AB (publ) is proud to announce that the diabetes management device Actiste® Mini today received market approval from the Ministry of Health & Prevention in the UAE.

PRODUCT

#insulin pen

View Analyst & Ambassador Comments
Go to original news
Mar 22,2021

BIOCORP and Diabeloop announce co-development agreement in personalized diabetes management

BIOCORP and Diabeloop, a young company, pioneer in therapeutic artificial intelligence with personalized and automated solutions for the management of diabetes treatment, announce today a cooperation agreement. This collaboration aims to unite the expertise of both companies to offer new, simple and personalized treatment options to people living with diabetes. Through this agreement and the integration of Mallya into Diabeloop’s technological environment, patients equipped with insulin pens will benefit from a unique, easy-to-use and personalized solution to improve their quality of care and life on a daily-basis. 

COLLABORATION PARTNERSHIP

#connected device

#insulin pen

#closed loop

View Analyst & Ambassador Comments
Go to original news
Mar 22,2021

Bigfoot Biomedical Secures up to $57 Million in Combined Debt and Equity Financing From Madryn Asset Management

Bigfoot Biomedical, a company dedicated to better health outcomes for people with insulin-requiring diabetes, announced that it has secured new financing of up to $57 million from Madryn Asset Management LP, an alternative asset management firm focused on investments in innovative health care companies.

FUNDING DEBT FINANCE
View Analyst & Ambassador Comments
Go to original news
Mar 29,2021

ABBOTT HOSTS CONFERENCE CALL FOR FIRST-QUARTER EARNINGS

The announcement will be followed by a live webcast of the earnings conference call at 8:30 a.m. Central time (9:30 a.m. Eastern), and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Mar 30,2021

Voluntis's 2020 annual results in line with the roadmap, demonstrating the success the new strategy, and confirmed confidence in the plan

Voluntis (Euronext Growth Paris, Ticker: ALVTX – ISIN: FR0004183960), a leader in the field of digital therapeutics, today announced its full year 2020 results as approved by the Board of Directors at its March 29, 2021 meeting. The audit procedures on the accounts have been performed. 

View Analyst & Ambassador Comments
Go to original news
Apr 12,2021

Wellthy Therapeutics: Tapping the power of digital tech

Digital healthcare is a proactive approach to healthcare that drives multiple customer touchpoints via real-time channels, so customers can make well-informed choices and build better habits, ultimately leading to a better quality of life. This is exactly what Wellthy Therapeutics, a digital therapeutics company with a presence in Asia and Europe, is working towards.

View Analyst & Ambassador Comments
Go to original news
Apr 05,2021

Welldoc and Dexcom Expand Strategic Partnership to Integrate Platforms and Offer Integrated Type 2 Diabetes Management Solution

Welldoc and Dexcom today announced the first customer for a new integrated offering to drive improved health for people with Type 2 diabetes. Welldoc will offer its BlueStar® digital health solution and the Dexcom G6 CGM system as a single platform offering for select employers and health systems, beginning with a Fortune 100 company.

COLLABORATION PARTNERSHIP

#product & service

#cgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES